Abstract
Highly publicised vaccine scares and recent debates about the risks suggest that public trust in immunisation programmes is fragile. For instance, the recent outbreak of Measles in Wales was the direct result of almost fifteen years of distrust for the MMR vaccine in the UK. This article shows how the latest science on risk communication will help critical actors, especially policy-makers, to build trust when they communicate risks to citizens and patients. The article offers policy advice on risk communication based on the results of three vaccines case studies. Five procedural principles which were developed for the UK government – the so-called “five As” of public risk communication are used to structure the discussion. Conclusions and recommendations suggest ways to move forward and build a two-way proactive risk communication practice.
Keywords: Hepatitis B, HPV, MMR, policy, regulation, risk communication, trust.
Current Drug Safety
Title:Risk Communication of Vaccines: Challenges in the Post-Trust Environment
Volume: 10 Issue: 1
Author(s): Frederic Bouder
Affiliation:
Keywords: Hepatitis B, HPV, MMR, policy, regulation, risk communication, trust.
Abstract: Highly publicised vaccine scares and recent debates about the risks suggest that public trust in immunisation programmes is fragile. For instance, the recent outbreak of Measles in Wales was the direct result of almost fifteen years of distrust for the MMR vaccine in the UK. This article shows how the latest science on risk communication will help critical actors, especially policy-makers, to build trust when they communicate risks to citizens and patients. The article offers policy advice on risk communication based on the results of three vaccines case studies. Five procedural principles which were developed for the UK government – the so-called “five As” of public risk communication are used to structure the discussion. Conclusions and recommendations suggest ways to move forward and build a two-way proactive risk communication practice.
Export Options
About this article
Cite this article as:
Bouder Frederic, Risk Communication of Vaccines: Challenges in the Post-Trust Environment, Current Drug Safety 2015; 10 (1) . https://dx.doi.org/10.2174/157488631001150407103916
DOI https://dx.doi.org/10.2174/157488631001150407103916 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Editorial (Thematic Issue: Nanotechnology for Drug Delivery Applications)
Current Drug Delivery Therapeutic Nanotechnology for Bone Infection Treatment – State of the Art
Current Drug Delivery Diagnostic Value of 99m Tc- Labeled-Ubiquicidin 29-41 (99m Tc-UBI) Scan in the Diagnosis of Vertebral Osteomyelitis
Current Medical Imaging Immunomodulatory and Anti-Inflammatory Activities of Statins
Endocrine, Metabolic & Immune Disorders - Drug Targets Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Withdrawn: Effects of Tofacitinib on Tfr/Tfh Balance and Expression of CXCL13 and TGF-β1 in Experimental Autoimmune Encephalomyelitis Rats
CNS & Neurological Disorders - Drug Targets Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Neurological Manifestations of COVID-19 and the Importance of Magnetic Resonance Imaging
CNS & Neurological Disorders - Drug Targets Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design